QIAGEN N.V. Articles
Test to assess risk of preterm birth approved by the FDA
QIAGEN N.V. has announced the U.S. regulatory approval of PartoSure, which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labour. The pre-market approval of PartoSure by the FDA follows successful uptake of the rapid, accurate test in more than 35 countries across Europe, the Middle East, Asia and Latin America. U.S. commercialisation of the PartoSure test is expected to begin in 2018.